Digital CBT reduced distress in patients with long-term physical health conditions
Participants who received COMPASS showed a clinically significant improvement after 12 weeks
Read More
Tag: COMPASS
Bayer files low-dose Xarelto/aspirin combo
Bayer is seeking permission to market in Europe its bloodthinner Xarelto in combination with aspirin to reduce the risk of cardiovascular events in patients with coronary or peripheral artery disease.
Read More
Bayer/Janssen’s Xarelto artery disease trial stopped early
Bayer/Janssen’s bloodthinner Xarelto has shown clear efficacy in preventing major cardiovascular events (MACE) in patients with coronary or peripheral artery disease taking part in the COMPASS trial, prompting an early halt to the late-stage study.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
